The CDC and FDA have approved the Beyfortus antibody shot, from drugmakers AstraZeneca and Sanofi, to prevent respiratory syncytial virus in babies from birth to 8 months old, or in children up to ...

A new CHOP study found only one in three eligible patients took Beyfortus when the medication that protects against severe ...

The largest US real-world study of BEYFORTUS (nirsevimab-alip) 50mg and 100mg Injection successfully met both of its co-primary endpoints, demonstrating that BEYFORTUS provides protection for babies ...

Beyfortus is recommended for every healthy newborn, and for some practices, that’s a lot of babies to cover. “You’re easily getting into the hundreds of thousands of dollars for a medium- ...

Parental trust in clinicians drove RSV vaccine uptake, while confusion and limited access to reliable information hindered ...

Find out whether you should get the RSV vaccine, known as Abrysvo, during pregnancy and when it's recommended.

Beyfortus contains the active ingredient nirsevimab-alip,* and Synagis contains palivizumab. If you have other questions about how Beyfortus and Synagis compare, talk with your child’s doctor.

Beyfortus, which will be marketed in the U.S. by Sanofi, is already approved in Canada, Europe, and the U.K. Sanofi did not immediately announce the U.S. price of the treatment.

When Beyfortus was approved over the summer, AstraZeneca and Sanofi, the two companies that manufacture the drug, said it would be available for babies in time for RSV season this year.

When Beyfortus was approved over the summer, AstraZeneca and Sanofi, the two companies that manufacture the drug, said it would be available for babies in time for RSV season this year.

That means that if pediatricians have only VFC-supplied Beyfortus in stock and need a dose for a baby who is not eligible for VFC coverage, they could use the dose, so long as they replace it.